Page 139 - Read Online
P. 139

sustained virologic response to interferon alpha plus ribavirin therapy   Gastroenterol Hepatol 2012;24:646-55.
               in naive chronic hepatitis C patients. BMC Gastroenterol 2009;9:5.  24.  Floreani A, Cazzagon N, Boemo DG, Baldovin T, Baldo V, Egoue J,
           19.  Yu JW, Sun  LJ, Zhao  YH,  Kang P,  Yan BZ. Impact of sex on   Antoniazzi S, Minola E. Female patients in fertile age with chronic
               virologic response rates in genotype 1 chronic hepatitis C patients   hepatitis  C, easy genotype,  and persistently  normal  transaminases
               with peginterferon alpha-2a and ribavirin treatment. Int J Infect Dis   have a 100% chance to reach a sustained virological response. Eur J
               2011;15:e740-6.                                   Gastroenterol Hepatol 2011;23:997-1003.
           20.  Akram M, Idrees M, Zafar S, Hussain A, Butt S, Afzal S, Rehman IU,   25.  Aziz  H, Athar MA, Murtaza  S, Irfan J,  Waheed  Y, Bilal  I, Raza
               Liaqat A, Saleem S, Ali M, Butt A. Effects of host and virus related   A. Predictors  of response to antiviral  therapy  in patients  with
               factors on interferon-α+ribavirin and pegylated-interferon+ribavirin   chronic hepatitis C from Pakistani population. Chin Med J (Engl)
               treatment outcomes in chronic Hepatitis C patients. Virol J 2011;8:234.  2011;124:1333-7.
           21.  Villela-Nogueira CA, Perez RM, de SegadasSoares JA, Coelho HSM.   26.  Hayashi J, Kishihara Y, Ueno K, Yamaji K, Kawakami Y, Furusyo N,
               Gamma-glutamyltransferase  (GGT) as an  independent  predictive   Sawayama Y, Kashiwagi S. Age-related response to interferon alfa
               factor  of sustained virologic  response in patients  with hepatitis  C   treatment in women vs men with chronic hepatitis C virus infection.
               treated  with interferon-alpha  and ribavirin.  J Clin  Gastroenterol   Arch Intern Med 1998;158:177-81.
               2005;39:728-30.                                27.  Sezaki H, Suzuki F, Kawamura Y, Yatsuji H, Hosaka T, Akuta N,
           22.  Hu CC, Lin CL, Kuo YL, Chien CH, Chen SW, Yen CL, Lin CY,   Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y,
               Chien RN. Efficacy and safety of ribavirin plus pegylated interferon   Kumada H. Poor response to pegylated interferon and ribavirin in
               alfa in geriatric patients with chronic hepatitis C. Aliment Pharmacol   older women infected with hepatitis C virus of genotype 1b in high
               Ther 2013;37:81-90.                               viral loads. Dig Dis Sci 2009;54:1317-24.
           23.  Innes HA,  Hutchinson SJ, Allen S, Bhattacharyya  D, Bramley P,   28.  Villa  E, Cammà C, Di Leo A, Karampatou A, Enea  M, Gitto S,
               Carman B, Delahooke TE, Dillon JF, Goldberg DJ, Kennedy N, Mills   Bernabucci V, Losi L, De Maria N, Lei B, Ferrari A, Vukotic R,
               PR, Morris J, Morris J, Robertson C, Stanley AJ, Hayes P; Hepatitis   Vignoli  P, Rendina M, Francavilla  A.  Peginterferon-Α_2B plus
               C Clinical Database Monitoring Committee.  Ranking predictors   ribavirin  is more effective  than  peginterferon-Α_2A plus ribavirin
               of a sustained viral response for patients with chronic hepatitis  C   in menopausal  women with chronic  hepatitis  C.  J Viral Hepat
               treated with pegylated interferon and ribavirin in Scotland.  Eur J   2012;19:640-9.
























































           130                                                             Hepatoma Research | Volume 2 | May 6, 2016
   134   135   136   137   138   139   140   141   142   143   144